|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Phage Biotechnology Corp. Engages The Bruckner Group To Find A Joint Commercialization Partner For Phage's Portfolio Of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms
11/6/2007 9:36:53 AM
WAKEFIELD, Mass.--(BUSINESS WIRE)--The Bruckner Group is pleased to announce that Phage Biotechnology Corp. (“Phage”) has engaged The Bruckner Group to find a partner to jointly commercialize Phage’s portfolio of recombinant biological therapies, the products of Phage’s development platforms and technologies. The Phage portfolio includes ten innovative and standard-of-care recombinant proteins, including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies (which will compete with monoclonal antibodies). Phage anticipates its portfolio will produce a revenue stream in the moderate nine-figure range within four years, and a medium to high ten-figure range eventually. Phage’s development platforms include a single-chain antibody development platform, a new proprietary pegylation technology, and a new recombinant protein manufacturing process that avoids existing protein process manufacturing patents.
|
|
|
|
|
|
|
|
|
|
|